Altimmune (ALT) Non-Current Debt (2012 - 2026)

Altimmune (ALT) posted quarterly Non-Current Debt of $34.5 million for Q1 2026, up 0.64% quarter-over-quarter from $34.3 million in Q4 2025.

Altimmune (ALT) Non-Current Debt (2012 - 2026) Analysis & Trends

Altimmune (ALT) has reported Non-Current Debt for 13 consecutive years, with $34.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $34.5 million; the TTM figure through Mar 2026 stood at $34.5 million (changed N/A YoY), while the FY2025 annual figure was $34.3 million, changed N/A from the prior year.
Non-Current Debt advanced to $34.5 million in Q1 2026 per ALT's latest filing, from $34.3 million in the prior quarter.
Across five years, Non-Current Debt topped out at $34.5 million in Q1 2026 and bottomed at $1.5 million in Q2 2022.
Historically, Non-Current Debt has averaged $11.2 million across 4 years, with a median of $4.5 million in 2022.
On a YoY basis, Non-Current Debt climbed as much as 215.06% in 2022 and fell as far as 5.64% in 2022.
Altimmune's Non-Current Debt stood at $4.6 million in 2022, then declined by 6.02% to $4.3 million in 2023, then soared by 696.45% to $34.3 million in 2025, then gained by 0.64% to $34.5 million in 2026.
Business Quant data shows ALT's Non-Current Debt at $34.5 million in Q1 2026, $34.3 million in Q4 2025, and $14.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Altimmune	571.75 Mn	571.75 Mn	-	34.74 Mn

Download Data